Theranos reaches settlement with Partner Fund Management. Tender offer recapitalizing major shareholders scheduled to close May 15.
Company to reimburse more than those whose tests were voided and corrected; Resolution ends all existing and potential claims against Theranos in the state.
CMS withdraws revocation of CLIA certificates and reduces civil monetary penalty; Theranos withdraws appeal, completing exit from the clinical lab business.
Theranos, Inc. announced that engineering and biomedical device design experts have joined the company’s newly created Technology Advisory Board (TAB).